Harrys A. Torres, M.D., F.A.C.P., F.I.D.S.A., F.A.A.S.L.D.

Peer-Reviewed Articles

1. George, M, Mustafayev, K, Ahmed, S, Thomas, SK, Jiang, Y, Patel, K, Torres, HA. Direct-Acting Antivirals Induce Lymphoproliferative Disease Response in HCV-Infected Patients With Indolent B-Cell Non-Hodgkin’s Lymphoma. Hematological Oncology 43(2), 2025. e-Pub 2025. PMID: 39921915.
2. Torres, HA, Mustafayev, K, Juneau, RP, Hwang, JP, Wang, LS, Angelidakis, G, Hawk, E, Granwehr, BP, Yepez Guevara, E, Ying, AK. Implementation of Universal Hepatitis C Virus Screening in a Tertiary Cancer Center. JNCCN Journal of the National Comprehensive Cancer Network 22(2D), 2024. e-Pub 2024. PMID: 38729204.
3. Shaikh, Abdullah S, Abraham, Susan C, Wang, Lan S, Torres HA, Zhang, HC. Viral Hepatitis B Reactivation With Delayed Cholestatic Effect Secondary to Acalabrutinib. ACG Case Reports Journal 11(6):p e01387, 2024. e-Pub 2024.
4. Torres HA, Mustafayev K, Juneau R, Hwang JP, Wang LS, Angelidakis G, Hawk E, Granwehr BP, Yepez Guevara E, Ying AK. Implementation of Universal Hepatitis C Virus Screening in a Tertiary Care Cancer Center. J Natl Compr Canc Netw 22(2D):e237332. e-Pub 2024.
5. Chiu CY, Jiang Y, Torres HA. Reply to High Specificity and Low Prevalence – Important Context for HIV Testing in US Cancer Patients. Clinical Infectious Diseases 79(2):575-6. e-Pub 2024.
6. Chiu CY, Mustafayev K, Bhatti MM, Jiang Y, Granwehr BP, Torres HA. False-reactive fourth-generation human immunodeficiency virus testing in cancer patients. Clinical Infectious Diseases. Publication selected as Editor’s Choice 78(3):674-680, 2024. e-Pub 2024.
7. Nardo M, Yilmaz B, Nelson BE, Torres HA, Wang LS, Granwehr BP, Song J, Dalla Pria HRF, Trinh VA, Glitza Oliva IC, Patel SP, Tannir NM, Kaseb AO, Altan M, Lee SS, Miller E, Zhang H, Stephen BA, Naing A. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis. The MD Anderson Cancer Center Experience. Oncologist 28(8):714-721, 2023.
8. Klingen JT, Mustafayev K, Yibirin M, Hwang J, Torres HA. False-Reactive Hepatitis B Surface Antigen Test Results in Cancer Patients. European Journal of Clinical Microbiology & Infectious Diseases 42(3):383-385, 2023. e-Pub 2023.
9. Chiu CY, Ahmed S, Thomas SK, Wang LS, Mustafayev K, Fayad LE, Wierda WG, Khawaja F, Torres HA. Hepatitis B virus reactivation in patients receiving Bruton tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk 23(8):610-615, 2023.
10. Chiu CY, Patel K, Thomas SK, Khawaja F, Dailey Garnes NJM, Lee HC, Ohanian M, Jiang Y, Wang LS, Hwang JP, Torres HA. Hepatitis B virus reactivation in patients with past HBV infection receiving anti-CD38 monoclonal antibodies. Hepatology International, 17(2):509-511, 2023. e-Pub 2023.
11. Yibirin M, Mustafayev K, Hosry J, Pundhir P, Klingen J, Yepez Guevara E, Granwehr BP, Kaseb A, Naing A, Patel S, Shah AY, Skoulidis F, Tawbi HA, Wang L, Miller E, Zhang HC, Zurita-Saavedra A, Torres HA. Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients with Solid Tumors. American Journal of Gastroenterology, 2023. Publication accompanied by an editorial 118(9):1609-1617, 2023. e-Pub 2023.
12. Chiu CY, Mustafayev K, Lee HC, Torres HA. Effect of anti-CD38 monoclonal antibodies on hepatitis C virus replication in chronically infected patients with multiple myeloma. Leukemia and Lymphoma 64(4):900-903, 2023. e-Pub 2023.
13. Raad I, Hachem R, Masayuki N, Datoguia T, Dagher H, Jiang Y, Subbiah V, Siddiqui B, Bayle A, Somer R, Cruz AF, Gorak E, Bhinder A, Mori N, Hamerschlak N, Shelanski S, Dragivich T, Kiat YEV, Fakhreddine S, Hanna PA, Chemaly RF, Mulanovich V, Adachi J, Borjan J, Khawaja F, Granwehr B, John T, Guevara EY, Torres HA, Ammakkanavar NR, Yibirin M, Reyes-Gibby CC, Pande M, Ali N, Rojo RD, Ali SM, Deeba RE, Chaftari P, Matsuo T, Ishikawa K, Hasegawa R, Aguado-Noya R, Á G, Puchol CT, Lee DG, Slavin M, Teh B, Arias CA. International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19. Impact of Risk Factors and Treatment Modalities on Survivorship. eLife 12:e81127, 2023. e-Pub 2023.
14. Chiu CY, Zhang HC, Westin J, Hosing C, Torres HA. Hepatitis E Virus Infection in Cancer Patients. Transplantation and Cellular Therapy 788.e1-788.e5(28):01559-7, 2022. e-Pub 2022.
15. Yibirin M, Horsry, J, Yepez Guevara E, Granwehr BP, Jiang Y, Mustafayev K, Angelidakis G, Torres HA. High sustained virologic response rate after 8 weeks of direct-acting antivirals in cancer patients with chronic hepatitis C virus infection. Eur J Gastroenterol Hepatol 34(10):1098-1101, 2022. e-Pub 2022.
16. Angelidakis G, Pritchard H, Yibirin M, Jiang Y, Mustafayev K, Torres HA. Impact of CD4+ T-cell count on sustained virologic response to direct-acting antivirals in hepatitis C virus monoinfected cancer patients: A prospective observational study. Diagnostic Microbiology & Infectious Disease 103(3):115719, 2022. e-Pub 2022.
17. Torres HA, Angelidakis G, Jiang Y, Economides MP, Mustafayev K, Yibirin MJ, Orlowski RZ, Champlin RE, Verstovsek S, Raad II. Serologic vs. molecular testing for screening for hepatitis C virus infection in patients with hematologic malignancies. Medicine 101(37):e30608, 2022. e-Pub 2022.
18. Torres HA, Lok AS, Suarez-Almazor ME, Warneke CL, Kaseb A, Miller E, Sturgis E, Foreman JT, Angelidakis G, Ahmed S, Ferrajoli A, Samaniego F, Hawk E, Hwang JP. Strategies to Identify Hepatitis C Virus Infection in Patients Receiving Anticancer Therapy: A Cross-Sectional Study. Support Care Cancer 29(1):97-105, 2021. e-Pub 2021.
19. Pundhir P, Roach LR, Bartek JR, Trask RP, Yibirin M, Yepez-Guevara E, Granwehr BP, Swalwell CR, Torres HA. Nursing Practice is Associated with High Risk for Hepatitis C Infection. Clinical Microbiology and Infection, 2021 27(9):1362-4, 2021. e-Pub 2021.
20. Pritchard, H, Hwang, JP, Angelidakis, G, Yibirin, M, Wang, LS, Miller, E, Torres HA. Hepatitis B Reactivation in Patients with Malignancies Receiving Direct-Aging Antivirals for Hepatitis C Virus Infection. Journal of Viral Hepatitis, 2021 28(5):844-8, 2021. e-Pub 2021.
21. Yibirin M, Pritchard H, Torres HA. False-positive Trypanosoma cruzi serology in a cancer patient receiving intravenous immunoglobulin. Diagnostic Microbiology & Infectious Disease. 2020 97(4):115-57, 2020. e-Pub 2020.
22. Angelidakis G, Mahale P, Jonasch E, Jiang Y, Torres HA. Chronic Hepatitis C Virus Infection and Genitourinary Cancers: A Case-Control Study. Seminars in Oncology, 2020 47(2-3):165-167, 2020. e-Pub 2020.
23. Hosry J, Miranda RN, Samaniego F, Angelidakis G, Torres HA. Clinicopathologic Characteristics of Follicular Lymphoma in Hepatitis C Virus -Infected Patients. Hematological Oncology 2020 (Highlighted as a Top Cited Article in 2020-2021 in Hematological Oncology) 38(3):301-308, 2020. e-Pub 2020.
24. Angelidakis G, Krishnan S, Cabrera NL, Jiang Y, Pushparaji B, Kaseb A, Torres HA. Virologic Impact of Radiotherapy in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma. Hepatology 72(2):775-777, 2020. e-Pub 2020.
25. Frigeni M, Besson C, Visco C, Fontaine H, Goldaniga M, Visentini M, Pulsoni A, Torres HA, Peveling-Oberhag J, Rossotti R, Zaja F, Rigacci L, Merli M, Dorival C, Alric L, Piazza F, Gentile M, Ferrari A, Pirisi M, Nassi L, Rattotti S, Frustaci A, Milella M, Cencini E, Defrancesco I, Ferretti VV, Bruno R, Hermine O, Arcaini L. Interferon-free compared to interferon-based regimens as First line therapy for B-cell lymphoproliferative disorders associated with hepatitis c virus infection. Leukemia 34(5):1462-1466, 2020. e-Pub 2020.
26. Malek AE, Nieto Y, Szvalb AD, Siddiqui S, Shafi MA, Hwang JP, Raad II, Torres HA. Hepatitis B virus-associated liver failure in a patient with B-cell non-Hodgkin lymphoma after anti-cancer therapy including ibrutinib. Clin Lymphoma Myeloma Leuk 20(3):e124-e127, 2020. e-Pub 2020.
27. Hwang JP, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Torres HA, † Bailey HH. Oncologic Implications of Chronic Hepatitis C Virus Infection. Publication accompanied by an editorial. Journal of Oncology Practice 15(12), 2019. e-Pub 2019.
28. Torres HA, Economides MP, Hosry J, angelidakis G, Kyvernitakis A, Mahale P, Jiang Y, Miller E, Blechacz B, Naing A, Samaniego F, Kaseb A, Raad II, Granwehr BP. Sofosbuvir-based therapy in hepatitis C virus-infected cancer patients: A prospective observational study. Publication accompanied by an editorial. Am J Gastroenterology 114:250-257, 2019. e-Pub 2019.
29. Pritchard H, Jandhyala D, Hosry J, Angelidakis G, Torres HA. Salvage Therapy in Cancer Patients with Hepatitis C without Sustained Virologic Response after Direct-Acting Antivirals – A Prospective Study. Journal of Gastroenterology and Hepatology Open 4(3):541-544, 2019. e-Pub 2019.
30. Torres HA, Pundhir P, Mallet V. Hepatitis C Virus Infection in Patients With Cancer: Impact on Clinical Trial Enrollment, Selection of Therapy, and Prognosis. Gastroenterology 157(4):909-916, 2019. e-Pub 2019.
31. Raad I, Chaftari AM, Torres HA, Fahmy E, Narouz LI, Bartek J, Hachem R. Challenge of hepatitis C in Egypt and hepatitis B in Mauritania. World J Hepatol 19(9):549-557, 2018. e-Pub 2018.
32. Hosry J, Miranda RN, Samaniego F, Economides MP, Torres HA. Clinicopathologic Characteristics and Outcomes of Transformed Diffuse Large B-Cell Lymphoma in Hepatitis C Virus-Infected Patients. International Journal of Cancer 142(5):940-948, 2018. e-Pub 2018.
33. Torres HA, Hosry J, Mahale P, Economides MP, Jiang Y, Lok AS. Hepatitis C virus reactivation in patients receiving cancer treatment: a prospective observational study. Publication accompanied by an editorial. Hepatology 67(1):36-47, 2018. e-Pub 2018.
34. Angelidakis G, Sturgis EM, Economides MP, Jiang Y, Torres HA. Chronic hepatitis C virus infection in patients with non-oropharyngeal head and neck cancers. Oral Oncology 85:103-105, 2018. e-Pub 2018.
35. Economides MP, Amit M, Mahale P, Hosry J, Jiang Y, Bharadwaj U, Sturgis EM, Torres HA. The Impact of Chronic Hepatitis C Virus Infection on Survival of Patients with Oropharyngeal Cancer. Cancer(124):960-5, 2018. e-Pub 2018.
36. Angelidakis G, Hwang JP, Dandachi D, Economides MP, Hosry J, Granwehr BP, Torres HA. Universal screening for hepatitis C: a needed approach in patients with hematologic malignancies. Journal of Viral Hepatitis 25:1102-1104, 2018. e-Pub 2018.
37. Hosry J, Angelidakis G, Kaseb A, Jiang Y, Torres HA. Inhibition of Hepatitis C Virus Replication Induced by Chemotherapy: a prospective observational study. Clinical Infectious Diseases 67(10):1635-1636, 2018. e-Pub 2018.
38. Hwang JP, Lok AS, Fisch MJ, Cantor SB, Barbo A, Lin HY, Foreman JT, Vierling JM, Torres HA, Granwehr BP, Miller E, Eng C, Simon GR, Ahmed S, Ferrajoli A, Romaguera J, Suarez-Almazor ME. Models to Predict Hepatitis B Virus Infection among Patients with Cancer Undergoing Systemic Anti-cancer Therapy: A Prospective Cohort Study. Publication accompanied by an editorial. Journal of Clinical Oncology 36:959-967, 2018. e-Pub 2018.
39. Mahale P, Engels EA, Li R, Torres HA, Hwang LY, Brown EL, Kramer JR. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. Gut 67(3):553-561, 2018. e-Pub 2018.
40. Dandachi D, Hassan M, Kaseb A, Angelidakis G, Torres HA. Hepatocellular carcinoma as second primary malignancy: exposing an overlooked presentation of liver cancer. Journal of Hepatocellular Carcinoma 5:81-86, 2018. e-Pub 2018.
41. Lu H, Lok AS, Warneke CL, Ahmed S, Torres HA, Matinez F, Suarez-Almazor ME, Foreman JT, Ferrajoli A, Hwang JP. Passive transfer of hepatitis B core antibody after intravenous immunoglobulin administration in patients with cancer: Retrospective Chart Review. Lancet Haematology 5(10):4474-e478, 2018. e-Pub 2018.
42. Economides MP, Mahale P, Turturro F, Hosry J, Samaniego F, Granwehr BP, Torres HA. Development of Non-Hodgkin Lymphoma as a Second Primary Cancer in Hepatitis C Virus-Infected Patients with a Different Primary Malignancy. Leukemia and Lymphoma 58(2):485-488, 2017. e-Pub 2017.
43. Oliver NT, Nieto YL, Blechacz B, Anderlini P, Ariza-Heredia E, Torres HA. Severe hepatitis C reactivation as an early complication of hematopoietic cell transplantation. Bone Marrow Transplantation 52(1):138-140, 2017. e-Pub 2017.
44. Economides MP, Ballester LY, Kumar VA, Jiang Y, Tarrand J, Prieto V, Torres HA, Kontoyiannis DP. Invasive mold infections of the central nervous system in patients with hematologic cancer or stem cell transplantation (2000-2016): uncommon, with improved survival but still deadly often. J Infect 75(6):572-580, 2017. e-Pub 2017.
45. Mahale P, Torres HA, Kramer JR, Hwang LY, Li R, Brown EL, Engels EA. Hepatitis C virus infection and the risk of cancer among elderly US adults: A registry-based case-control study. Cancer 123(7):1202-1211, 2017. e-Pub 2017.
46. Hassan MM, Bortus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Shalaby A, Morris J, Kaseb A. Estrogen Replacement Reduces Risk and Improves Survival of Hepatocellular Carcinoma in American Women. Clinical Gastroenterology and Hepatology 15(11):1791-1799, 2017. e-Pub 2017.
47. Varma A, Saliba RM, Torres HA, Afrough A, Hosing C, Khouri IF, Nieto Y, Shah ND, Parmar S, Bashir Q, Ahmed S, Jones RB, Kebriaei P, Olson A, Shpall EJ, Alousi AM, Qazilbash MH, Champlin RE, Popat UR. Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. Bone Marrow Transplantation 51(7):999-1001, 2016. e-Pub 2016.
48. Iqbal T, Mahale P, Turturro F, Kyvernitakis A, Torres HA. Prevalence and association of hepatitis C virus infection with different types of lymphoma. International Journal of Cancer 138(4):1035-7, 2016. e-Pub 2016.
49. Torres HA, Roach LR, Mahale P, Economides MP, Blechacz B, Miller E, Borchardt R, Rashid A, Oo TH, Shukla B, Farida M, Ericsson CD, Granwehr BP, Raad II. Transdisciplinary Approach to Managing Hepatitis C Virus Infection in Patients at a Tertiary Care Cancer Center. The Journal of the National Comprehensive Cancer Network 14(9):1185-8, 2016. e-Pub 2016.
50. Jain P, Verstovsek S, Wang W, Loghavi S, Torres HA, Estrov Z, Patel KP, Pemmaraju N. DNMT3A, TET2 and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. Leukemia and Lymphoma 57(8):1969-73, 2016. e-Pub 2016.
51. Mahale P, Sturgis EM, Tweardy DJ, Ariza-Heredia EJ, Torres HA. Association between Hepatitis C Virus and Head and Neck cancers. Journal of the National Cancer Institute 108(8), 2016. e-Pub 2016.
52. Kyvernitakis A, Mahale P, Popat UR, Jiang Y, Hosry J, Champlin RE, Torres HA. Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents. Biology of Blood and Marrow Transplantation 4(22):717-22, 2016. e-Pub 2016.
53. Mahale P, Turturro F, Romaguera JE, Fowler N, Torres HA. The Effect of Different Rituximab-Containing Chemotherapy Strategies on Hepatitis C Viremia. Leukemia and Lymphoma 57(6):1487-90, 2016. e-Pub 2016.
54. Hosry J, Mahale P, Turturro F, Miranda RN, Economides MP, Granwehr BP, Torres HA. Antiviral therapy improves overall survival in Hepatitis C virus-infected patients who develop Diffuse Large B-cell Lymphoma. International Journal of Cancer 139(11):2519-28, 2016. e-Pub 2016.
55. Torres HA, Vauthey JN, Economides MP, Mahale P, Kaseb A. Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment. Journal of Hepatology 65(4):862-4, 2016. e-Pub 2016.
56. Kyvernitakis A, Torres HA, Jiang Y, Chamilos G, Lewis RE, Kontoyiannis DP. Initial Use of Combination Treatment Does Not Impact Survival of 106 Patients with Hematologic Malignancies and Mucormycosis: a Propensity Score Analysis. Clinical Microbiology and Infection 22(9):811.el-811.e8, 2016. e-Pub 2016.
57. Arcaini L, Besson C, Frigeni M, Fontaine H, Goldaniga M, Casato M, Visentini M, Torres HA, Loustaud-Ratti V, Peveling-Oberhag J, Fabris P, Rossotti R, Zaja F, Rigacci L, Rattotti S, Bruno R, Merli M, Dorival C, Alric L, Jaccard A, Pol S, Carrat F, Ferretti VV, Visco C, Hermine O. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis c virus infection. Blood 128(21):2527-2532, 2016. e-Pub 2016.
58. Economides MP, Mahale P, Kyvernitakis A, Turturo F, Kantarjian H, Naing A, Hosry J, Shigle TL, Kaseb A, Torres HA. Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer. Alimentary Pharmacology & Therapeutics 44(11-12):1235-1241, 2016. e-Pub 2016.
59. Torres HA, Chong PP, De Lima M, Friedman MS, Giralt S, Hammond SP, Kiel PJ, Masur H, McDonald GB, Wingard JR, Gambarin-Gelwan M. Hepatitis C Virus Infection among Hematopoietic Cell Transplant Donors and Recipients. Biology of Blood and Marrow Transplantation 21(11):1870-82, 2015. e-Pub 2015.
60. Mahale P, Thomas SK, Kyvernitakis A, Torres HA. Management of multiple myeloma complicated by hepatitis C virus reactivation - the role of new antiviral therapy. Open Forum Infectious Dis 3(1):ofv211, 2015. e-Pub 2015.
61. Mahale P, Kaseb AO, Hassan MM, Torres HA. Hepatocellular carcinoma as a second primary cancer in patients with chronic hepatitis C virus infection and a nonliver first primary cancer. Digestive and Liver Disease, 2015 47(4):348-9, 2015. e-Pub 2015.
62. Kyvernitakis A, Taremi M, Blechacz, B, Hwang J, Jiang Y, Mahale P, Torres HA. Impact of Hepatitis E Virus Seropositivity on Chronic Liver Disease of Cancer Patients with Hepatitis C Virus Infection. Hepatology Research(45):1146-51, 2015. e-Pub 2015.
63. Torres HA, Mahale P, Blechacz B, Miller ED, Kaseb A, Fowler N, Herlong HF, Jiang Y, Raad II, Kontoyiannis DP. Effect of Hepatitis C Virus Infection in Patients with Cancer: Addressing a Neglected Population. Journal of the National Comprehensive Cancer Network 13(1):41-50, 2015. e-Pub 2015.
64. Torres HA, Mahale P. Most patients with HCV-associated lymphoma present with mild liver disease: A call to revise antiviral treatment prioritization. Liver Int 35(6):1661-4, 2015. e-Pub 2015.
65. Hwang JP, Granwehr B, Torres HA, Suarez-Almazor ME, Giordano TP, Barbo A, Lin HY, Fisch MJ, Chiao EY. HIV testing in patients with cancer at the initiation of therapy at a large US comprehensive cancer center. J Oncol Pract 11(5):384-390, 2015. e-Pub 2015.
66. Hassan MM, Abdel-Wahab R, Kaseb A, Phan AT, El-Serag HB, Morris J, Singh Raghav KP, Lee JS, Vauthey JN, Shalaby A, Torres HA, Amos CI, Li D. Significant Impact of Early Adulthood Obesity on Risk and Prognosis of Hepatocellular Carcinoma in the United States. Gastroenterology 149(1):119-29, 2015. e-Pub 2015.
67. Mahale P, Okhuysen PC, Torres HA. Does chemotherapy cause hepatitis C viral relapse in cancer patients who were successfully treated with antivirals?. Clin Gastroenterol Hepatol 6(12):1051-1054, 2014. e-Pub 2014.
68. Hwang JP, Suarez-Almazor ME, Torres HA, Palla SL, Huang DS, Fisch MJ, Lok ASF. Hepatitis C screening in cancer patients receiving chemotherapy. J Oncol Pract 3(10):167-74, 2014. e-Pub 2014.
69. Torres HA, Kaseb A, Mahale P, Miller E, Frenette C. Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series. Journal of Hepatocellular Carcinoma(1):109-114, 2014. e-Pub 2014.
70. Kyvernitakis A, Jabbour E, Torres HA. Sustained Virological Response after 6 Weeks of Therapy with a First-generation Hepatitis C Virus Protease Inhibitor. Clin Infect Dis 58(9):1342-4, 2014. e-Pub 2014.
71. Kyvernitakis A, Duvic M, Mahale P, Torres HA. Interferon-based Treatment for Patients with Mycosis Fungoides and Hepatitis C Virus Infection: A Case Series. Am J Clin Dermatol 15(5):451-6, 2014. e-Pub 2014.
72. Torres HA, Rallapalli V, Saxena A, Granwehr BP, Viola GM, Ariza-Heredia E, Adachi JA, Chemaly RF, Marfatia R, Jiang Y, Mahale P, Kyvernitakis, Fanale MA, Mulanovich V. Efficacy and safety of antiretrovirals in HIV-infected patients with cancer. Clin Microbiol Infect 20(10):O672-9, 2014. e-Pub 2014.
73. Torres HA, Mahale P, Miller ED, Oo TH, Frenette C, Kaseb AO. Coadministration of Telaprevir and Transcatheter Arterial Chemoembolization in the Management of Hepatitis C Virus-Associated Hepatocellular Carcinoma. World J Hepatol 5(6):332-5, 2013. e-Pub 2013.
74. Georgiadou SP, Lewis RE, Best L, Torres HA, Champlin R, Kontoyiannis DP. The impact of prior invasive mold infections in leukemia patients who undergo allo-SCT in the era of triazole-based secondary prophylaxis. Bone Marrow Transplant 48(1):141-3, 2013. e-Pub 2013.
75. Chemaly RF, Torres HA, Munsell MF, Shah DP, Rathod DB, Bodey GP, Hosing C, Saifan C, Raad II, Champlin RE. An Adaptive Randomized Trial of Intermittent Dosing Schedule of Aerosolized Ribavirin in Cancer Patients with Respiratory Syncytial Virus Infections. Journal of Infectious Diseases 54(3):218-22, 2012. e-Pub 2012.
76. Torres HA, Adachi JA, Roach LR, Smith KM, Mahale P, Davila M, Raad II. Hepatitis C Clinic operated by Infectious Disease at a Comprehensive Cancer Center – Help is on the way. Clinical Infectious Diseases 54(5):740-742, 2012. e-Pub 2012.
77. Mahale P, Kontoyiannis DP, Chemaly RF, Jiang Y, Lewis R, Hwang J, Davila M, Torres HA. Acute exacerbation and viral reactivation of chronic hepatitis C infection in cancer patients. Publication accompanied by an editorial. Journal of Hepatology 57(6):1177-85, 2012. e-Pub 2012.
78. Mahale P, Kaseb AO, Davila M, Torres HA. The Effect of Transcatheter Arterial Chemoembolization on Hepatitis C viremia. Oncologist 17(9):21-3, 2012. e-Pub 2012.
79. Torres HA, Nevah MI, Barnett BJ, Mahale P, Kontoyiannis DP, Hassan MM, Raad II. Hepatitis C Virus Genotype Distribution Varies by Underlying Disease Status among Patients in the Same Geographic Region: A Retrospective Multicenter Study. J Clin Virol 54(3):218-22, 2012. e-Pub 2012.
80. Aisenberg GM, Torres HA, Tarrand J, Safdar A, Bodey GP, Chemaly RF. Herpes Simplex Virus Lower Respiratory Tract Infection in Patients with Solid Tumors. Cancer 115(1):199-206, 2009. e-Pub 2009.
81. Raad II, Hanna HA, Boktour M, Jiang Y, Torres HA, Afif C, Kontoyiannis DP, Hachem RY. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 22:496–503, 2008. e-Pub 2008.
82. Chemaly RF, Torres HA, Hachem R, Kontoyiannis DP, Safdar A, Raad II. Human Herpesvirus-6 DNAemia in Immunosuppressed Adult Patients with Leukemia at risk for mold infection. Haematologica 93(1):157-8, 2008. e-Pub 2008.
83. Torres HA, Aguilera EA, Safdar A, Rohatgi N, Raad II, Sepulveda C, Luna M, Kontoyiannis DP, Chemaly RF. Fatal cytomegalovirus pneumonia in patients with haematological malignancies: an autopsy-based case–control study. Clinical Microbiology and Infection 14:1160–6, 2008. e-Pub 2008.
84. Hachem RY, Boktour MR, Hanna HA, Husni RN, Torres HA, Afif C, Kontoyiannis DP, Raad II. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer 112(6):1282-7, 2008. e-Pub 2008.
85. Torres HA, Aguilera EA, Mattiuzzi G, Cabanillas M, Rohatgi N, Sepulveda C, Kantarjian HH, Safdar A, Raad II, Chemaly RF. Characteristics and Outcome of Respiratory syncytial virus infection in patients with leukemia. Haematologica 92:1216-1223, 2007. e-Pub 2007.
86. Torres HA, Bull L, Arduino RC. Tongue Hyperpigmentation in a Caucasian Patient Coinfected With HIV and Hepatitis C During Peginterferon Alfa-2b and Ribavirin Therapy. Am J Gastroenterol 102(6):1334-1335, 2007. e-Pub 2007.
87. Arias CA, Torres HA, Singh KV, Panesso D, Moore J, Wagner A, Murray BE. Failure of daptomycin monotherapy in the treatment of endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin Infect Dis 45:1343–6, 2007. e-Pub 2007.
88. Torres HA, Barnett B, Arduino RC. Alopecia associated to ritonavir-boosted atazanavir therapy. AIDS 21(10):1391-1392, 2007. e-Pub 2007.
89. Chemaly RF, Torres HA, Aguilera EA, Mattiuzzi G, Cabanillas M, Kantarjian H, Gonzalez V, Safdar A, Raad II. Neuraminidase Inhibitors Improve Outcome of Patients with Leukemia and Influenza Infection: An Observational Study. Clin Infect Dis 44:964-7, 2007. e-Pub 2007.
90. Torres HA, Barnett B, Arduino RC. Use of fosamprenavir, a sulfa-containing protease inhibitor, in HIV-infected patients with glucose-6-phosphate dehydrogenase deficiency. Clin Infect Dis 44(6):887-8, 2007. e-Pub 2007.
91. Torres HA, Kontoyiannis DP, Aguilera EA, Younes A, Luna MA, Tarrand JJ, Nogueras GM, Raad II, Chemaly RF. Cytomegalovirus infection in patients with lymphoma: an important cause of morbidity and mortality. Clin Lymphoma Myeloma 6(5):393-8, 2006. e-Pub 2006.
92. Torres HA, Hanna HA, Graviss L, Chaiban G, Hachem R, Chemaly RF, Girgawy E, Raad II. Chest Tube related multidrug-resistant Staphylococcus aureus empyema: Could the chest tube be coated with antiseptics?. Infect Control Hosp Epidemiol 27(2):195-7, 2006. e-Pub 2006.
93. Torres HA, Chemaly RF, Storey R, Aguilera EA, Nogueras GM, Safdar A, Rolston KVI, Raad II, Kontoyiannis DP. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis 5(6):382-8, 2006. e-Pub 2006.
94. Torres HA, Kontoyiannis DP, Bodey GP, Adachi JA, Luna MA, Tarrand JJ, Nogueras GM, Raad II, Chemaly RF. Gastrointestinal Cytomegalovirus Disease In Patients With Cancer. European Journal of Cancer 41(15):2268-2279, 2005. e-Pub 2005.
95. Kontoyiannis DP, Boktour M, Hanna H, Torres HA, Hachem R, Raad II. Itraconazole Added to a Lipid Formulation of Amphotericin B Does Not Improve Outcome of Primary Treatment of Invasive Aspergillosis. Cancer 103(11):2334-7, 2005. e-Pub 2005.
96. Torres HA, Prieto VG, Raad II, Reddy BT, Kontoyiannis DP. Proven pulmonary cryptococcosis due to capsule-deficient Cryptococcus neoformans does not differ clinically from proven pulmonary cryptococcosis due to capsule-intact C. neoformans. Mycoses 48:21-24, 2005. e-Pub 2005.
97. Lionakis MS, Lewis RE, Torres HA, Albert ND, Raad II, Kontoyiannis DP. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn Microbiol Infect Dis 52(1):15-20, 2005. e-Pub 2005.
98. Chemaly RF, Torres HA, Hachem RY, Nogueras GM, Aguilera EA, Younes A, Luna MA, Rodriguez G, Tarrand JJ, Raad II. Cytomegalovirus Pneumonia in Patients with Lymphoma. Cancer 104(6):1213-1220, 2005. e-Pub 2005.
99. Torres HA, Kontoyiannis DP, Rolston KVI. High-dose fluconazole therapy for cancer patients with solid tumors and candidemia: an observational, noncomparative retrospective study. Support Care Cancer 12(7):511-6, 2004. e-Pub 2004.
100. Kontoyiannis DP, Torres HA, Chagua M, Hachem R, Tarrand JJ, Bodey GP, Raad II. Trichosporonosis in a Tertiary Care Cancer Center: Risk Factors, Changing Spectrum and Determinants of Outcome. Scand J Infect Dis 36(8):564-569, 2004. e-Pub 2004.
101. Steinbach WJ, Jr BD, Kontoyiannis DP, Perfect JR, Lutsar I, Marr KA, Lionakis MS, Torres HA, Jafri H, Walsh TJ. Infections Due to Aspergillus terreus: A Multicenter Retrospective Analysis of 83 Cases. Clin Infect Dis 39(2):192–8, 2004. e-Pub 2004.
102. Torres HA, Bodey GP, Tarrand JJ, Kontoyiannis DP. Protothecosis in Patients with Cancer: cases series and literature review. Clinical Microbiology and Infection 9:786-92, 2003. e-Pub 2003.
103. Antoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Tarrand J, Han XY, Rolston KVI, Safdar A, Raad II, Kontoyiannis DP. Candidemia in a Tertiary Care Cancer Center: In Vitro Susceptibility and its Correlation with Outcome of Initial Antifungal Therapy. Medicine (Baltimore) 82:309-21, 2003. e-Pub 2003.
104. Torres HA, Rivero GA, Lewis RE, Raad II, Kontoyiannis DP. Aspergillosis caused by non-fumigatus Aspergillus species: Risk factors and in vitro susceptibility compared with Aspergillus fumigatus. Diagn Microbiol Infect Dis 46:25-28, 2003. e-Pub 2003.
105. Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, Champlin R, Kantarjian H, Bodey GP, Raad II. Efficacy and toxicity of the caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of pulmonary aspergillosis in patients with hematologic malignancies. Cancer 98(2):292-9, 2003. e-Pub 2003.
106. Rivero GA, Torres HA, Rolston KVI, Kontoyiannis DP. Listeria monocytogenes infection in patients with cancer. Diagn Microbiol Infect Dis 47:393-8, 2003. e-Pub 2003.
107. Torres HA, Bodey GP, Rolston KVI, Kantarjian HM, Raad II, Kontoyiannis DP. Infections in Patients with Aplastic Anemia: Experience at a Tertiary Care Cancer Center. Cancer 98(1):86-93, 2003. e-Pub 2003.
108. Shaikh ZH, Torres HA, Walsh GL, Champlin RE, Kontoyiannis DP. Open Lung Biopsy in Bone Marrow Transplant Recipients Has a Poor Diagnostic Yield for a Specific Diagnosis. Transpl Infect Dis 4(2):80-4, 2002. e-Pub 2002.
109. Torres HA, Reddy BT, Raad II, Tarrand J, Bodey GP, Hanna HA, Rolston KVI, Kontoyiannis DP. Nocardiosis in Patients with Cancer. Medicine (Baltimore) 81(5):388-97, 2002. e-Pub 2002.
110. Torres HA, Rivero GA, Kontoyiannis DP. Endemic Mycoses in a Cancer Hospital. Medicine (Baltimore) 81(3):201-12, 2002. e-Pub 2002.
111. Reddy BT, Torres HA, Kontoyiannis DP. Breast Implant Infection Caused by Trichosporon Beigelii. Scand J Infect Dis 34(2):143-4, 2002. e-Pub 2002.
112. Kontoyiannis DP, Reddy BT, Torres HA, Luna M, Lewis RE, Tarrand J, Bodey GP, Raad II. Pulmonary candidiasis in patients with cancer: an autopsy study. Clin Infect Dis 34(3):400-3, 2002. e-Pub 2002.

Invited Articles

1. Mustafayev K, Mallet V, Torres HA. Journal of Immunotherapy and Precision Oncology. Management of hepatitis B virus and hepatitis C virus infections in cancer patients receiving immune checkpoint inhibitors 7(2):111-121, 2024. e-Pub 2024.
2. Mustafayev K, Torres HA. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. Clin Microbiol Infect, Editor’s Choice S1198-743X(22):00119-7, 2022. e-Pub 2022.
3. Hwang JP, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Torres HA, Bailey HH. Oncologic Implications of Chronic Hepatitis C Virus Infection. Journal of Oncology Practice 15(12):629-37, 2019. e-Pub 2019.
4. Hwang JP, Torres HA. Hepatitis B virus and hepatitis C virus infection in immunocompromised patients. Curr Opin Infect Dis 31(6):535-541, 2018. e-Pub 2018.
5. Torres HA, Shigle TL, Hammoudi N, Link JT, Samaniego F, Kaseb A, Mallet V. The oncologic burden of hepatitis C virus infection: A clinical perspective. A Cancer Journal for Clinicians 67(5):411-431, 2017. e-Pub 2017.
6. Economides MP, Shigle TL, Torres HA. Should direct-acting antiviral drugs be concomitantly used with chemotherapeutic drugs in hepatitis C virus-infected patients with cancer?. Aliment Pharmacol Ther 45(5):758-759, 2017. e-Pub 2017.
7. Torres HA, McDonald GB. How I treat Hepatitis C virus infection in patients with hematologic malignancies. Blood 128(11):1449-57, 2016. e-Pub 2016.
8. Borchardt R, Torres HA. Challenges in managing Hepatitis C infection in cancer patients. World Journal of Gastroenterology 11(20):2771-6, 2014. e-Pub 2014.
9. Torres HA, Mulanovich VE. Management of HIV infection in patients with cancer receiving chemotherapy. Clin Infect Dis 59(1):106-14, 2014. e-Pub 2014.
10. Torres HA, Davila M. Reactivation of Hepatitis B and Hepatitis C virus in Patients with Cancer. Nat Rev Clin Oncol 9(3):156-66, 2012. e-Pub 2012.
11. Torres HA, Arduino RC. Fosamprenavir calcium plus ritonavir for HIV infection. Expert Rev Anti Infect Ther 5(3):349-63, 2007. e-Pub 2007.
12. Torres, HA. Febrile neutropenia: an overview. Pan American Society of Infectology-Asociación Panamericana de Infectología 16, 2003. e-Pub 2003.
13. Torres HA, Raad II, Kontoyiannis DP. Infections caused by Fusarium species. J Chemother 15:28-35, 2003. e-Pub 2003.
14. Mustafayev K, Short NJ, Chien KS, Daver N, Khawaja F, Torres HA. Hepatitis B virus reactivation in patients receiving Janus kinase inhibitors.

Other Articles

1. Mallet, V, Torres, HA Hepatitis E virus infection after CAR T-cell treatment. British Journal of Haematology 206(3):1020-1021, 2025. PMID: 39622628.
2. Săndulescu O, Gjeruldsen Dudman S, Gmizic I, Garcia F, Harvala H, Hasanoglu I, Janjua NZ, Kowalska J, Mallet V, Maticic M, Mondelli MU, Op de Coul ELM, Perumalswami PV, Özkaya Şahin G, Said Z, Sánchez-Avila JF, Velikov P, Weis N, Zidovec-Lepej S, Torres HA Global Hepatitis C Elimination: Updates, Challenges, and Opportunities from Real-World Experiences in Europe and North America. Hepatology.
3. Torres, HA, Mustafayev, K, Nastoupil, L, Shelburne, S Severe reactivation of seronegative occult hepatitis B after chemotherapy for lymphoma. The Lancet 403(10434):1372-1373, 2024. PMID: 38582568.
4. Ellickalputhenpura BE, Torres HA* Histoplasmosis. JAAPA 25(12):18, 25-6, 2012.
5. Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II Posaconazole: A Broad Spectrum Triazole. Lancet Infect Dis 5(12):775-85, 2005.

Editorials

1. Torres HA, Mallet V. Hepatitis E virus infection after CAR T-cell treatment: an important complication in patients already facing significant health challenges. British Journal of Haematology 206(3):1020-1021.
2. Terrault N, Torres HA, Price J, Hepatology BD. The National Hepatitis C Elimination Program. AASLD’s Coalition and Call to Action 78(2):371-374, 2023.
3. Torres HA, Chemaly RF. Viral Infection or Reactivation in Patients during Treatment with Dasatinib: A call for screening?. Leuk Lymphoma 48(12):2308-9, 2007.

Abstracts

1. Mustafayev K, Arvelaez J, Naing A, Thomas SK, Patel KK, Pemmaraju V, Daver NG, Jiang Y, Yepez Guevara E, Torres HA. The Use of Direct-Acting Antivirals to Enhance Access to Cancer Clinical Trials for Patients with Chronic Hepatitis C Virus Infection and Cancer. The Liver Meeting 2025. e-Pub 2025.
2. Shaikh AS, Mustafayev K, Koutroumpakis F, Arvelaez Pascucci J, Zhang HC, Patel K, Ahmed S, Torres HA. Hepatitis B Virus Reactivation in Patients with Hematologic Malignancies Receiving Chimeric Antigen Receptor T-Cell Therapy. Liver Meeting 2025. e-Pub 2025.
3. Torres HA, Mustafayev K, Nastoupil LJ, Shelburne SA. Hepatitis B virus reactivation in a cancer patient with seronegative occult hepatitis B infection. The 34th European Congress of Clinical Microbiology and Infectious Diseases - ECCMID 2024, 2024. e-Pub 2024.
4. Mustafayev K, Naing A, Thomas SK, Patel KK, Pemmaraju N, Daver NG, Jiang Y, Yepez Guevara E, Torres HA. Treatment of Chronic Hepatitis C Virus Infection To Increase Access To Cancer Clinical Trials In Patients With Hematologic Malignancies. The Annual Meeting of American Society of Clinical Oncology (ASCO), 2023. e-Pub 2023.
5. Hwang J, Heredia N, Asrani S, Foreman J, Warneke C, Abraham J, Ankoma-Sey C, Ankoma-Sey V, Basen-Engquist K, Booker A, Gambrill C, Green K, Harris C, Le A, Ma J, McNeil L, Nguyen L, Torres HA, Caracostis A. Prevalence of risk factors for liver fibrosis and associations of serum biomarkers with liver fibrosis in a Houston community clinic. The Annual Meeting of American Society of Clinical Oncology (ASCO), 2023. e-Pub 2023.
6. Chiu CY, Ahmed S, Thomas SK, Wang LS, Mustafayev K, Fayad LE, Wierda WG, Khawaja F, Torres HA. Hepatitis B virus reactivation in patients receiving Bruton tyrosine kinase inhibitors. 4th Symposium on Infectious Diseases in the Immunocompromised, 2023. e-Pub 2023.
7. Hwang JP, Heredia N, Asrani S, Foreman J, Warneke CL, Abraham J, Ankoma-Sey C, Ankoma-Sey V, Basen-Engquist K, Booker A, Gambrill C, Green K, Harris C, Le A, Ma J, McNeill L, Nguyen L, Torres HA, Caracostis A. Prevalence and predictors of liver fibrosis in a Houston community clinic. The Liver Meeting 2023, 2023. e-Pub 2023.
8. Malek AE, Chaftari P, Okhuysen PC, Dagher H, Torres HA, Hachem R, Chaftari AM, Viola GM, Mulanovich VE, Raad II. Isoniazid therapy for latent tuberculosis infection in patients with cancer treated with checkpoint inhibitors immunotherapy. IDWeek 2021; Sept 28-Oct 2, 2021, 2021. e-Pub 2021.
9. Torres HA, Angelidakis G, Jiang Y, Economides MP, Yibirin MJ, Orlowski RZ, Champlin RE, Verstovsek S, Raad II. Serologic vs. molecular testing for screening for hepatitis C virus infection in patients with hematologic malignancies with and without prior hematopoietic cell transplant recipients. ID Week 2020, 2020. e-Pub 2020.
10. Malek AE, Nieto Y, Szvalb AD, Siddiqui S, Shafi MA, Hwang JP, Raad II, Torres HA. Hepatitis B Virus Reactivation in Patients with Hematologic Malignancies after Anticancer Therapy Which Included Ibrutinib. IDWeek 2019. October 2-6, Washington, DC, 2019. e-Pub 2019.
11. Angelidakis G, Krishnan S, Cabrera NL, Jiang Y, Pushparaji B, Lyos SA, Kaseb A, Torres HA. Hepatitis C Virus Reactivation in Patients with Hepatocellular Carcinoma receiving radiotherapy: A Case-Control Study. Abstract #0577. The Liver Meeting 2019, November 8-12,2019, Boston, MA, 2019. e-Pub 2019.
12. Pritchard H, Jandhyala D, Hosry J, Angelidakis G, Torres HA. Salvage Therapy in Cancer Patients with Hepatitis C without Sustained Virologic Response after Direct-Acting Antivirals – A Prospective Study. Abstract # 1604. The Liver Meeting 2019, November 8-12, 2019, Boston, MA, 2019. e-Pub 2019.
13. Angelidakis G, Mahale P, Jiang Y, Torres HA. Association between Chronic Hepatitis C Virus Infection and Genitourinary Cancers. Abstract #0579. The Liver Meeting 2019, November 8-12, 2019, Boston, MA, 2019. e-Pub 2019.
14. Pundhir P, Angelidakis G, Naing A, Granwehr BP, Torres HA. Hepatitis C Virus Infection is a Major Exclusion Criterion for Oncology Clinical Trials: A Call to Revisit Eligibility Criteria in the Era of Direct-Acting Antivirals. The Liver Meeting 2018, November 9-13, 2018, San Francisco, CA, 2018. e-Pub 2018.
15. Hosry J, Angelidakis G, Granwehr B, Torres HA. Short-duration of Direct-acting Antivirals in Hepatitis C Virus Infected Cancer Patients. IDWeek 2018, October 3-7, 2018, San Francisco, CA, 2018. e-Pub 2018.
16. Pritchard H, Hwang JP, Torres HA. Hepatitis B Reactivation in Patients with Malignancies Undergoing Treatment for Hepatitis C Infection with Direct-Acting Antivirals. IDWeek 2018, October 3-7, 2018, San Francisco, CA, 2018. e-Pub 2018.
17. Hosry J, Naing A, Torres HA. Immune Checkpoint Inhibitors in Solid Tumor Patients with Chronic Hepatitis C Virus Infection: A prospective case-series. IDWeek 2018, October 3-7, 2018, San Francisco, CA, 2018. e-Pub 2018.
18. Angelidakis G, Nowbakht C, Torres HA. Late Viral Relapse after Direct Acting Antiviral Treatment in Hepatitis C Virus-Infected Cancer Patients. IDWeek 2018, October 3-7, 2018, San Francisco, CA, 2018. e-Pub 2018.
19. Torres HA, Lok AS, Suarez-Almazor ME, Warneke CL, Miller E, Kaseb A, Sturgis E, Angelidakis G, Ahmed S, Ferrajoli A, Samaniego F, Hawk E, Hwang JP. Hepatitis C Virus Risk Tool for Patients with Cancer. The 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, 2018. Chicago, IL, 2018. e-Pub 2018.
20. Angelidakis G, Sturgis EM, Economides MP, Jiang Y, Torres HA. Impact of Chronic Hepatitis C Virus Infection in Patients with Non-Oropharyngeal Cancers. The 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, 2018. Chicago, IL, 2018. e-Pub 2018.
21. Dandachi D, Hassan M, Kaseb A, Angelidakis G, Torres HA. Hepatocellular carcinoma as second primary malignancy: exposing an overlooked presentation of liver cancer. The International Liver Congress 2018, Paris France, 2018. e-Pub 2018.
22. Pritchard H, Angelidakis G, Jiang Y, Torres HA. Impact of CD4+ T-cell count on sustained virologic response to direct-acting antivirals in HIV-negative cancer patients with chronic hepatitis C. The International Liver Congress 2018, Paris France, 2018. e-Pub 2018.
23. Economides MP, Hosry J, Angelidakis G, Kaseb A, Torres HA. Use of Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma. IDWeek 2017, October 4-8, San Diego, CA, 2017. e-Pub 2017.
24. Hwang JP, Lok AS, Warneke CL, Ahmed S, Torres HA, Barbo A, Suarez-Almazor ME, Ferrajoli A, Lu H. Passive Transfer of Hepatitis B Core Antibody after Intravenous Immunoglobulin Administration in Patients Receiving Anti-cancer Therapy. The Liver Meeting® October 20-24, Washington, DC, 2017. e-Pub 2017.
25. Hosry J, Miranda RN, Turturro F, Economides MP, Samaniego F, Torres HA. Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in Hepatitis C virus-infected patients: A Case-Control Study of 84 patients. The 53rd Annual Meeting of American Society of Clinical Oncology (ASCO), Chicago, IL June 2-6,, 2017. e-Pub 2017.
26. Torres HA, Economides MP, Kyvernitakis A, Mahale P, Hosry J, Jiang Y, Kaseb A, Raad II, Granwehr BP. Sofosbuvir-based therapy in patients with chronic hepatitis C virus infection and malignancies – A prospective observational study of 136 patients. The International Liver Congress™ April, 19-23, Amsterdam, Netherlands, 2017. e-Pub 2017.
27. Economides MP, Sturgis EM, Amit M, Hosry J, Mahale P, Jiang Y, Torres HA. Impact of Chronic Hepatitis C Virus infection in patients with Oropharyngeal Cancer. The 53rd Annual Meeting of American Society of Clinical Oncology (ASCO),Chicago, IL. Abstract e17556 June 2-6,, 2017. e-Pub 2017.
28. Economides MP, Ballester L, Kumar V, Jiang Y, Tarrand JJ, Prieto V, Torres HA, Kontoyiannis DP. Invasive Mold Infections of the Central Nervous System in patients with hematologic cancer (2000-2016): Uncommon but deadly. IDWeek 2017, October 4-8, San Diego, CA, 2017. e-Pub 2017.
29. Hosry J, Economides MP, Samaniego F, Torres HA. Direct-acting antivirals induce lymphoproliferative disease response in HCV-infected patients: A prospective case series. IDWeek 2017, October 4-8, San Diego, CA, 2017. e-Pub 2017.
30. Torres HA, Economides MP, Kyvernitakis A, Mahale P, Hosry J, Jiang Y, Turturro F, Kaseb A, Raad II, Granwehr BP. Sofosbuvir-Based Therapy in Patients with Chronic Hepatitis C Virus Infection and Malignancies - A Prospective Observational Study of 143 Patients. The 53rd Annual Meeting of American Society of Clinical Oncology (ASCO),Chicago, IL. Abstract e18152 June 2-6,, 2017. e-Pub 2017.
31. Pritchard H, Jandhyala D, Economides MP, Hosry J, Torres HA. Salvage Therapy in Cancer Patients With Hepatitis C Infection Failing Direct-Acting Antivirals – A Prospective Study. IDWeek 2017, October 4-8, San Diego, CA, 2017. e-Pub 2017.
32. Angelidakis G, Hwang JP, Economides M, Hosry J, Dandachi D, Granwehr B, Torres HA. Prevalence and screening of chronic hepatitis C virus infection in patients with hematologic malignancies: A call for universal screening. The Liver Meeting® October 20-24, Washington, DC, 2017. e-Pub 2017.
33. Hosry J, Samaniego F, Turturro F, Economides MP, Torres HA. Effect of Lenalidomide on Hepatitis C Viremia in Cancer Patients: A Case Series. The 58th Annual Meeting of the American Society of Hematology, December 3-6, 2016, San Diego, California, 2016. e-Pub 2016.
34. Hassan M, Abdel-Wahab R, Kaseb AO, Shalaby A, Botrus G, Lacin S, Morris JS, Amin HM, Wolff RA, Hwang JP, Li D, Torres HA, Shalaby A, Lenzi R, Yao JC, Joss JA, Jalal PK, Khaderi S, Ballard K, Hawk E. Hepatocellular Carcinoma Screening in High-Risk Populations in the United States. The Liver Meeting® 2016, November 11-15, Boston, MA, 2016. e-Pub 2016.
35. Economides MP, Mahale P, Hosry J, Jiang Y, Granwehr BP, Torres HA. Sofosbuvir-Based Therapy in Patients with Chronic Hepatitis C Virus Infection and Malignancies – A Prospective Observational Study of 60 Patients. IDWeek 2016, October 26-30, New Orleans, LA, 2016. e-Pub 2016.
36. Hosry J, Mahale P, Turturro F, Miranda RN, Economides MP, Granwehr BP, Torres HA. Effect of antiviral therapy on overall survival rate in Hepatitis C virus-infected patients with Diffuse Large B-cell Lymphoma. The 52nd Annual Meeting of American Society of Clinical Oncology (ASCO), Chicago, IL. June 3-7, 2016. e-Pub 2016.
37. Torres HA, Hosry J, Mahale P, Economides MP, Lok AS. Hepatitis C virus reactivation in patients with cancer: A prospective observational study of 91 patients. The Liver Meeting® 2016, November 11-15, Boston, MA, 2016. e-Pub 2016.
38. Hassan M, Abdel-Wahab R, Wolff RA, Botrus G, Shalaby A, Li D, Torres HA, Morris JS, Ballard K, Hawk E, Shalaby A, Amin HM, Yao JC, Lenzi R, Joss JA, Jalal PK, Khaderi S, Lacin S, Kaseb AO. Growth Hormone and Hepatocellular Carcinoma. The Liver Meeting® 2016, November 11-15, Boston, MA, 2016. e-Pub 2016.
39. Economides MP, Mahale P, Kyvernitakis A, Turturo F, Kantarjian H, Naing A, Hosry J, Shigle TL, Kaseb A, Torres HA. Concomitant use of antivirals and chemotherapy in hepatitis C virus-infected patients with cancer. EASL Special Conference: New Perspectives in Hepatitis C Virus Infection. The Roadmap for Cure, September 23-24, 2016, Paris, France, 2016. e-Pub 2016.
40. Hosry J, Economides MP, Kaseb A, Hassan MM, Torres HA. Effect of Sorafenib on Hepatitis C Viremia in Cirrhotic Patients with Hepatocellular Carcinoma. IDWeek 2016, October 26-30, New Orleans, LA, 2016. e-Pub 2016.
41. Torres HA, Roach L, Mahale P, Granwehr B, Blechacz B, Miller E, Borchardt R, Shukla B, Ericsson CD, Raad II. Transdisciplinary approach to managing HCV infection in patients at a tertiary care cancer center. IDWeek 2015, October 7-11, San Diego, CA. Open Forum Infectious Diseases, 2015. e-Pub 2015.
42. Kyvernitakis A, Mahale P, Sastry J, Torres HA. The effect of sofosbuvir-based antiviral therapy on CD4+ T-cell counts in hepatitis C virus monoinfected cancer patients. The Liver Meeting 2015® 66th Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA. Hepatology November 13-17 60 (1)(suppl; abstr 1030), 2015. e-Pub 2015.
43. Kyvernitakis A, Mahale P, Torres HA. Safety and tolerability of different antiviral regimens for chronic hepatitis c virus infection in cancer patients. Hepatol Int 2015 9(Suppl , abstract 1235):S272, 2015. e-Pub 2015.
44. Mahale P, Sturgis EM, Torres HA. Hepatitis C virus seropositivity and head and neck cancers – a new trio. The 51st Annual Meeting of American Society Of Clinical Oncology, J Clin Oncol 33(suppl; abstr 6041), 2015. e-Pub 2015.
45. Kyvernitakis A, Mahale P, Popat UR, Jiang Y, Champlin RE, Torres HA. Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents. The 51st Annual Meeting of American Society Of Clinical Oncology, J Clin Oncol 33(suppl; abstr 7090), 2015. e-Pub 2015.
46. Mahale P, Kyvernitakis A, Kantarjian H, Naing A, Turturro F, Kaseb A, Torres HA. Concomitant use of chemotherapy and antivirals in hepatitis C virus infected cancer patients. The Liver Meeting 2015® 66th Annual Meeting of the American Association for the Study of Liver Diseases, November 13-17, 2015, San Francisco, CA. Hepatology 60(1)(suppl;abstr 1160), 2015. e-Pub 2015.
47. Iqbal T, Mahale P, Turturro F, Kyvernitakis A, Torres HA. Prevalence of Hepatitis C Virus Infection in Patients with Lymphoma. The 51st Annual Meeting of American Society Of Clinical Oncology, J Clin Oncol 33(suppl; abstr e19506), 2015. e-Pub 2015.
48. Mahale P, Kyvernitakis A, Torres HA. Q Predictors of Sustained Virological Response in Cancer Survivors with Hepatitis C Virus Infection Receiving Antiviral Therapy. IDWeek 2014. Philadelphia, PA, October 8-12, 2014. e-Pub 2014.
49. Mahale P, Kaseb AO, Hassan M, Blechacz B, Kyvernitakis A, Torres HA. Development of hepatocellular carcinoma as a second primary cancer in hepatitis C virus-infected patients with a different primary malignancy. 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago, IL, May 30-June 3, 2014. e-Pub 2014.
50. Mahale P, Fowler N, Romaguera JE, Turturro F, Torres HA. The Effect of Different Rituximab-Containing Chemotherapy Strategies on Hepatitis C Viremia. The 56th Annual Meeting of the American Society of Hematology, San Francisco, California. December 6-9, 2014. e-Pub 2014.
51. Mahale P, Romaguera JE, Turturro F, Fowler N, Torres HA. Development of Non-Hodgkin’s Lymphoma as Second Primary Cancer in Hepatitis C Virus-Infected Patients with a Different Primary Malignancy. The 56th Annual Meeting of the American Society of Hematology, San Francisco, California. December 6-9, 2014. e-Pub 2014.
52. Rashid A, Torres HA, Jorewicz L, De La Garza II R. Incidence and characteristics of depression in cancer patients with chronic Hepatitis C infection. 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago, IL, May 30-June 3, 2014. e-Pub 2014.
53. Mahale P, Thomas SK, Kyvernitakis A, Torres HA. Hepatitis C virus reactivation following thalidomide therapy. The American Association for the Study of Liver Diseases, November 7-11, 2014, Boston, MA, and at the American Association for the Study of Liver Diseases (AASLD)/European Association for the Study of the Liver (EASL) 2014 Special Conference on Hepatitis C. New York City, NY. September 12 – 13, 2014. e-Pub 2014.
54. Kyvernitakis A, Oo TH, Kroll MH, Afshar-Kharghan V, Mahale P, Torres HA. Incidence and Management of Hematological Toxicities Associated with Treatment of Hepatitis C Virus Infection in Cancer Patients. The 56th Annual Meeting of the American Society of Hematology, San Francisco, California. December 6-9, 2014. e-Pub 2014.
55. Abdel-Wahab R, Mohamed HE, Ahmed R, Kanwal PS, Kaseb A, Herlong HF, Young KC, Botrus G, Torres HA, Shalaby AS, Hassan M. Prognostic Effect of Statins on Hepatocellular Carcinoma in Presence and Absence of Metformin intake. The Liver Meeting® 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA. November 7-11, 2014. e-Pub 2014.
56. Torres HA, Rallapalli V, Saxena A, Granwehr BP, Viola G, Ariza E, Chemaly RF, Jiang Y, Marfatia R, Shelburne S, Mulanovich V. Efficacy and Safety of Antiretrovirals in HIV-Infected Patients with Cancer. Abstract and Poster Walk at 53rd ICAAC, 2013. e-Pub 2013.
57. Mahale P, Miller ED, Blechacz B, Herlong HF, Davila M, Torres HA. The effect of antiviral therapy on progression of liver disease in Hepatitis C Virus-infected patients with malignancies. The Liver Meeting®, AASLD’s 64th Annual Meeting in Washington, 2013. e-Pub 2013.
58. Torres HA, Mahale P, Raad II, Kontoyiannis DP. Hepatitis C Virus Infection in Patients with Cancer: A Single-Institution Experience in 642 Patients. The Liver Meeting®, AASLD’s 64th Annual Meeting in Washington, DC, 2013. e-Pub 2013.
59. Granwehr BP, Merriman K, Grimes R, Torres HA, Mulanovich V, Routbort M, Chiao E. HIV Testing in a Cancer Center. IDWeek 2013. October 2-6, San Francisco, CA, 2013. e-Pub 2013.
60. Torres HA, Mahale P, Kontoyiannis DP, Hollinger FB. Occult Hepatitis B and Occult Hepatitis C Viremia in Patients with Hematological Malignancies. Abstracts of the 2012 American Society Clinical Oncology. (ASCO) Annual Meeting, 2012. e-Pub 2012.
61. Torres HA, Mahale P, Saxena A, Afshar-Kharghan V, Kroll MH, Oo TH. Use of Growth Factors in Treatment of Hepatitis C Viral Infection in Cancer Patients. 2012 Annual Meeting of the American Society of Hematology in Atlanta, 2012. e-Pub 2012.
62. Saxena A, Hassan M, Mahale P, Kontoyiannis DP, Torres HA. Screening for HCV Infection in a National Cancer Institute-designated cancer center. The Liver Meeting®, 2012. e-Pub 2012.
63. Torres HA, Kaseb A, Mahale P, Miller E, Frenette C. Telaprevir containing regimen against hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation - a case series. The Liver Meeting®, 2012. e-Pub 2012.
64. Torres HA, Mahale P. Does chemotherapy cause hepatitis C viral relapse in cancer patients who achieved sustained virological response?. The Liver Meeting®, 2012. e-Pub 2012.
65. Mahale P, Kontoyiannis DP, Torres HA. High cumulative dose of rituximab is associated with acute exacerbation of chronic hepatitis C virus infection in patients with cancer. The Liver Meeting®, 2012. e-Pub 2012.
66. Hassabo MH, Iwasaki M, Soliman MK, Kaseb A, Torres HA, Li D, Xiao L, Yasmin A, Morris J, Hassan M. Impact of metformin on HCC prognosis in presence and absence of HCV infection. The Liver Meeting, 2012. e-Pub 2012.
67. Torres HA, Mahale P, Ying J, Kontoyiannis DP. Rituximab and Gemcitabine are Associated with Acute Exacerbation of Chronic Hepatitis C Virus Infection in Patients with Cancer. Abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases. The Liver Meeting®, 2011. e-Pub 2011.
68. Torres HA, Davila M, Mulanovich VE, Granwehr BP, Miller E, Nevah MI, Mishra L, Kontoyiannis DP, Raad II. Hepatitis C Clinic at a Comprehensive Cancer Center: The successful story of multidisciplinary efforts. Abstracts of the 49th Annual Meeting of the Infectious Diseases Society of America, 2011. e-Pub 2011.
69. Mahale P, Kaseb AO, Davila M, Torres HA. The effect of transcatheter arterial chemoembolization on hepatitis c virus kinetics in patients with HCV associated hepatocellular carcinoma. Abstracts of the 47th American Society Clinical Oncology (ASCO) Annual Meeting, 2011. e-Pub 2011.
70. Torres HA, Nevah MI, Barnett BJ, Mahale P, Kontoyiannis DP, Mishra L, Hassan MM, Raad II. Variation of hepatitis C virus genotype distribution between geographically related patients: A retrospective multicenter study. Abstracts of the 47th American Society Clinical Oncology (ASCO) Annual Meeting, 2011. e-Pub 2011.
71. Mahale P, Torres HA. Changes in Hepatitis C Virus RNA Levels in Cancer Patients Undergoing Chemotherapy or Immunosuppressive Therapy. Abstracts of the 49th Annual Meeting of the Infectious Diseases Society of America, 2011. e-Pub 2011.
72. Torres HA, Mahale P, Davila M, Mulanovich V, Granwehr B, Kontoyiannis DP, Raad II. Hepatitis C Virus Infection in Cancer Patients: The Story of a Forgotten Population, 2010. e-Pub 2010.
73. Rathod DB, Torres HA, Munsell M, Bodey G, Davis M, Saifan C, Raad II, Champlin R, Chemaly RF. Continuous Versus Intermittent Dose Schedule of Aerosolized Ribavirin for Treatment of Respiratory Syncytial Virus upper respiratory tract infection in patients with Hematological Malignancies: An Adaptive Randomized Trial. Abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2009. e-Pub 2009.
74. Mahale P, Davila M, Chemaly RF, Lewis RE, Hwang JP, Kontoyiannis DP, Torres HA. Acute Exacerbation of Chronic Hepatitis C in Cancer Patients. Abstracts of the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA), Vancouver, British Columbia, Canada, 2010.
75. Torres HA, Raad II, Reddy BT, Kontoyiannis DP. Pulmonary Cryptococcosis Due to Capsule-Deficient Cryptococcus Neoformans. Abstracts of the 41st Annual Meeting of Infectious Diseases Society of America (IDSA), Abstract 352, San Diego, California, USA, 2003.
76. Torres HA, Younes A, Aguilera EA, Kontoyiannis DP, Luna MA, Tarrand JJ, Nogueras GM, Raad II, Chemaly RF. Cytomegalovirus Infection in Patients with Lymphoma. Abstracts of the 42nd Annual Meeting of Infectious Diseases Society of America (IDSA), Boston, Massachusetts, USA, 2004.
77. Torres HA, El-Osta H, Hachem RY, Mattiuzzi G, Cabanillas M, Jain A, Raad II, Chemaly RF. Parainfluenza Virus Infection in Patients with Leukemia Commonly Involves the Lower Respiratory Tract. Abstracts of the 44th Annual Meeting of Infectious Diseases Society of America (IDSA), Abstract 1286, Toronto, Canada, 2006.
78. Chiu CY, Patel K, Thomas SK, Khawaja F, Dailey Garnes NJM, Lee HC, Ohanian M, Jiang Y, Wang LS, Hwang JP, Torres HA. Hepatitis B virus reactivation in patients receiving anti-CD38 monoclonal antibodies. The Liver Meeting 2022. Washington, DC.
79. Yibirin M, Mustafayev K, Hosry J, Pundhir P, Klingen J, Yepez Guevara E, Granwehr BP, Kaseb A, Naing A, Patel S, Shah AY, Skoulidis F, Tawbi HA, Wang L, Miller E, Zhang HC, Zurita-Saavedra A, Torres HA. Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients with Solid Tumors. The Liver Meeting 2022. Washington, DC.
80. Rolston KVI, Torres HA, Kontoyiannis DP. High Dose Fluconazole Therapy for Cancer Patients with Candidemia. Abstracts of the 40th Annual Meeting of Infectious Diseases Society of America (IDSA), Abstract 350, Chicago, Illinois, USA, 2002.
81. Torres HA, Aguilera EA, Rohatgi N, Raad II, Sepulveda C, Safdar A, Kontoyiannis DP, Chemaly RF. Cytomegalovirus Pneumonia in Patients with Hematologic Malignancies: An Autopsy-Based Case-Control Study. Abstracts of the 44th Annual Meeting of Infectious Diseases Society of America (IDSA), Abstract 787, Toronto, Canada, 2006. Abstracts of the Texas Infectious Diseases Society 2007 Annual Meeting. San Antonio, Texas, 2007. Second Place Clinical Research Award on the Texas Infectious Diseases Society 2007 Annual Meeting. San Antonio, Texas, 2007.
82. Mustafayev K, Yepez Guevara E, Pemmaraju N, Jabbour E, Ghayas IC, DiNardo CD, Ravin R, Torres HA. The Liver Meeting 2024. San Diego, California, November 15-19, 2024.
83. Antoniadou A, Torres HA, Lewis RE, Raad II, Thornby J, Tarrand J, Rolston KVI, Han XY, Bodey GP, Kontoyiannis DP. In vitro Susceptibility and Resistance of Bloodstream Candida Species in a Tertiary Care Cancer Center: Correlation with Outcome of Antifungal Therapy. Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Abstract M-1491, San Diego, California, USA, 2002.
84. Pappas PG, Morgan J, Hajjeh RA, Network (TRANSNET) ATTAIS. Prospective Surveillance for Invasive Fungal Infections in Hematopoetic Stem Cell and Solid Organ Transplant Recipients in the United States (Preliminary Results). Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Abstract 3826, Chicago, Illinois, USA, 2003.
85. Raad II, Hanna HA, Boktour MR, Torres HA, Kontoyiannis DP, Hachem RY. The Combination of Caspofungin and Voriconazole as Primary and Salvage Therapy of Invasive Aspergillosis in Hematologic Malignancy Patients. Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, California, USA, 2006.
86. Torres HA, Aguilera EA, Mattiuzzi G, Cabanillas M, Rohatgi N, Sepulveda C, Kantarjian H, Raad II, Chemaly RF. Respiratory Syncytial Virus Infection in Patients With Leukemia: To Treat or Not To Treat? Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Slide presentation, Washington, DC, USA, 2005.
87. Torres HA, Cáceres AM, Simonovis N. C Reactive Protein in patients with Human Immunodeficiency Virus infection: Potential Role in Diagnosis and Monitoring of Treatment. Abstracts of the 13th International Symposium on Infections in the Immunocompromised, Granada, Spain, 2004. Int J Infect Dis. 2004;8 Suppl:S30 (Abstract).
88. Lewis RE, Torres HA, May GS, Raad II, Thornby J, Rolston KVI, Updhyaya D, Bodey GP, Kontoyiannis DP. In vitro Susceptibility and Tolerance of Aspergillus Species in a Tertiary Care Cancer Center: Correlation with Invasive Aspergillosis and its Outcome. Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Abstract M-1491, San Diego, California, USA, 2002.
89. Mustafayev K, Short NJ, Chien KS, Daver N, Khawaja F, Torres HA. Hepatitis B virus reactivation in patients receiving Janus kinase inhibitors. The Liver Meeting 2024. San Diego, California, November 15-19, 2024.
90. Klingen JT, Yibirin M, Hwang JP, Torres HA. False-Positive Hepatitis B Surface Antigen in Cancer Patients. IDWeek 2021, Sept 28-Oct 2, 2021.
91. Reddy BH, Torres HA, Raad II, Rolston KVI, Whimbey EE, Jacobson K, Tarrand JJ, Bodey GP, Kontoyiannis DP. Nocardiosis in Cancer Patients. Abstracts of the 39th Annual Meeting of Infectious Diseases Society of America (IDSA), Abstract 67, San Francisco, California, USA, 2001.
92. Chemaly RF, Torres HA, Rohatgi N, Kontoyiannis DP, Safdar A, Kantarjian H, Daugherty T, Sepulveda C, Hachem R, Raad II. Human Herpesviruses-6 Viremia is Associated with Donor Granulocyte Transfusions in Heavily Immunosuppressed Patients with Leukemia. Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, USA, 2005.
93. Torres HA, Storey R, Chemaly RF, Aguilera EA, Luna MA, Rolston KVI, Raad II, Kontoyiannis DP. Pneumocystis Jiroveci Pneumonia in a Cancer Center: Influence of HIV Status to Presentation and Outcome. Abstracts of the 42nd Annual Meeting of Infectious Diseases Society of America (IDSA), Boston, Massachusetts, USA, 2004.
94. Torres HA, Mustafayev K, Juneau R, Hwang JP, Wang LS, Angelidakis G, Granwehr BP, Yepez Guevara E, Ying AK. Implementation of Universal Hepatitis C Virus Screening in a Tertiary Care Cancer Center. The Liver Meeting 2023.
95. Lionakis MS, Lewis RE, Torres HA, Kontoyiannis DP. In Vitro Susceptibility of Aspergillus Clinical Isolates to Amphotericin B, Itraconazole and Voriconazole by E-test and the Effect of Prior Antifungal Exposure. Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Abstract 2526, Chicago, Illinois, USA, 2003.
96. Chitasombat MN, Jiang Y, Torres HA, Nguyen K, Tarrand J, Chemaly RF. Cytomegalovirus Infection in Patients with Chronic Lymphocytic Leukemia. Abstracts of the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA), Vancouver, British Columbia, Canada, 2010.
97. Torres HA, Rodriguez G, Aguilera EA, Rohatgi N, Raad II, Safdar A, Chemaly RF. Cytomegalovirus Adrenalitis: A Challenging Diagnosis in Patients with Hematologic Malignancies. Abstracts of the 44th Annual Meeting of Infectious Diseases Society of America (IDSA), Abstract 1285, Toronto, Canada, 2006.
98. Yibirin M, Pundhir P, Yepez-Guevara E, Granwehr BP, Kaseb A, Patel S, Naing A, Shah AY, Skoulidis F, Tawbi HA, Zhang HC, Wang L, Miller E, Torres HA. Safety of Immune Checkpoint Inhibitors in Cancer Patients with Chronic Hepatitis C Infection: A Prospective Observational Study. The Liver Meeting 2020, November 13-17, 2020.
99. Torres HA, Rolston KVI, Raad II, Kontoyiannis DP. Infections in Patients with Aplastic Anemia: The Experience of a Tertiary Care Cancer Center. The 41th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Abstract K-1244, Chicago, Illinois, USA, 2001.
100. Aisenberg GM, Torres HA, Tarrand J, Safdar A, Chemaly RF. Herpes Simplex Virus in Lower Respiratory Tract Secretions in Patients with Solid Tumors: Shedding or Infection? Abstracts of the 43rd Annual Meeting of Infectious Diseases Society of America (IDSA), San Francisco, California, USA, 2005.
101. Raad II, Ramos E, Hachem R, Jiang Y, Torres HA, Al-Akhrass F, Kontoyiannis DP, Safdar A. Are White Blood Cell Transfusions Useful in the Salvage Treatment of Invasive Aspergillosis in Neutropenic Hematologic Malignancy Patients? Abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Abstract M-1058, San Francisco, California, USA, 2009.
102. George M, Mustafayev K, Ahmed S, Thomas SK, Jiang Y, Patel K, Torres HA. Direct-Acting Antivirals Induce Lymphoproliferative Disease Response In Hepatitis C Virus-Infected Patients With Indolent B-Cell Non-Hodgkin's Lymphoma: A Prospective Observational Study. The Liver Meeting 2023.
103. Aguilera EA, Torres HA, Gonzalez VR, Raad II, Chemaly RF. The Impact of Influenza Epidemic with a Predominant Mismatched Circulating Strain with the Vaccine Strain on Patients with Hematologic Malignancies during Winter 2003-2004. Abstracts of the 15th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America. Los Angeles, California, USA, 2005.
104. Raad II, Hanna HA, Boktour MR, Torres HA, Kontoyiannis DP, Hachem RY. Posaconazole Compared to High Dose Lipid Formulations of Amphotericin B as Salvage Therapy for Invasive Aspergillosis in Patients with Hematologic Malignancy. Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, California, USA, 2006.
105. Torres HA, Kontoyiannis DP. Protothecosis in Cancer Patients. Abstracts of the 39th Annual Meeting of Infectious Diseases Society of America (IDSA), Abstract 273, San Francisco, California, USA, 2001.
106. Pundhir P, Roach LR, Bartek JR, Yepez-Guevara E, Granwehr BP, Yibirin M, Swalwell CR, Torres HA. Nursing Practice is Associated with High Risk for Hepatitis C Infection. The Liver Meeting, November 13-17, 2020.
107. Hachem R, Ramos E, Kassis C, Jiang Y, Torres HA, Kontoyiannis D, Raad II. The Combination of Posaconazole and Echinocandins as Salvage Therapy of Invasive Aspergillosis in Hematologic Malignancy Patients. Abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Abstract M-1046, San Francisco, California, USA, 2009.
108. Yibirin M, Yepez-Guevara E, Granwehr BP, Pundhir P, Torres HA. Short-Duration of Direct-Acting Antivirals in Cancer Patients with Chronic Hepatitis C Virus Infection. The Liver Meeting, November 13-17, 2020.
109. Hachem RY, Boktour MR, Hanna HA, Torres HA, Afif C, Kontoyiannis D, Raad II. Amphotericin B Lipid Complex vs. Liposomal Amphotericin B Monotherapy of Invasive Aspergillosis in Patients with Hematological Malignancy. Abstracts of the 43rd Annual Meeting of Infectious Diseases Society of America (IDSA), San Francisco, California, USA, 2005.
110. Mahale P, Kyvernitakis A, Hosry J, Popat UR, Torres HA. Acute exacerbation and reactivation of chronic hepatitis C virus infection in hematopoietic cell transplant recipients. Bone Marrow Transplant Tandem Meeting, Honolulu, Hawaii, February 18 – 22, 2016.
111. Mustafayev K, Jiang Y, Yepez Guevara E, Torres HA. Risk of Hepatitis B Virus Reactivation in Patients with Rheumatoid Arthritis Treated with Janus Kinase Inhibitors: A Meta-Analysis. International Immunocompromised Host Society (ICHS) 24th Biennial Symposium.
112. Rivero GA, Torres HA, Rolston KVI, Kontoyiannis DP. Listeriosis in Patients with Cancer. Abstracts of the 2002 Trainee Recognition Day, Abstract 187. The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA, 2002.
113. Jandhyala D, Economides MP, Hosry J, Torres HA. The Role of Resistance Testing Guiding Salvage Therapy in Cancer Patient With Hepatitis C Infection Failing Direct-Acting Antivirals. A Prospective Observational Study. Antimicrobial Resistance Symposium: Novel Frontiers in Antimicrobial Research January 19-20, 2017, Houston, TX.
114. . International Virtual Sessions on Management of Viral Hepatitis in Patients with Cancer. The Global Hepatitis Summit 2025. Los Angeles, California, USA, March 18-21, 2025.
115. Granwehr BP, Merriman KW, Shelal Z, Bazerbashi H, Brock PA, Gonzalez CE, Torres HA, Rice T. HIV Testing in a Cancer Center Emergency Department. The 2016 ASCO Quality Care Symposium, Phoenix, Arizona February 26-27, 2016.
116. Aguilera EA, Torres HA, Mattiuzzi G, Cabanillas M, Kantarjian H, Gonzalez V, Raad II, Chemaly RF. Influenza Infection In Adult Patients with Leukemia: The Impact Of Neuraminidase Inhibitors. Abstracts of the 1st Annual Symposium of Infections in Cancer. Houston, Texas, USA, 2005.
117. Donato-Santana C, Oliver NT, Barbo AG, Lin H, Foreman JT, Torres HA, Granwehr BP, Chiao EY, Hwang JP. Management and Clinical Outcomes of Cancer Patients with Human Immunodeficiency Virus after Cancer Therapy. The SGIM 39th Annual Meeting - Generalists Engaged in Population Health, Hollywood Florida. The SGIM 39th Annual Meeting - Generalists Engaged in Population Health, Hollywood Florida, May 11-14, 2016.
118. Hwang JP, Lok AS, Fisch MJ, Cantor SB, Barbo A, Lin HY, Foreman JT, Vierling JM, Torres HA, Granwehr B, Miller E, Suarez-Almazor ME. Predicting Hepatitis B Virus Infection among Patients with Cancer Undergoing Systemic Anti-cancer Therapy: A Prospective Cohort Study. 2017 Society of General Internal Medicine (SGIM) Annual Meeting. Washington, DC. April, 19-22, 2017.
119. Pundhir P, Ying AK, Rodriguez MA, Sturgis EM, Angelidakis G, Torres HA. Implementation of Universal Hepatitis C Virus Screening in a Tertiary Care Cancer Center. AASLD / EASL HCV Special Conference, February 1-2, 2019, Miami, FL.
120. Hosry J, Kyvernitakis A, Mahale P, Champlin R, Torres HA. Interferon-Free Regimens in Hepatitis C Virus-infected Hematopoietic Cell Transplant Recipients. Bone Marrow Transplant Tandem Meeting, Honolulu, Hawaii February 18-22, 2016.
121. Torres HA, Luna MA, Kontoyiannis DP, Tarrand JJ, Nogueras GM, Chemaly RF. Gastrointestinal Cytomegalovirus Disease in Patients with Cancer. Abstracts of the Internal Medicine & The Cancer Patient. Houston, Texas, USA, 2004.
122. Kyvernitakis A, Torres HA, Jiang Y, Chamilos G, Lewis RE, Kontoyiannis DP. Initial Use of Combination Treatment Does Not Impact Early Survival of 106 Patients with Hematologic Malignancies and Mucormycosis: a Propensity Score Analysis. Submitted in May 2015 to the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) / International Congress of Chemotherapy and Infection (ICC). September 17–21, 2015, San Diego, CA. and 7th Trends in Medical Mycology, October 9-12, 2015 Lisbon, Portugal.
123. Torres HA, Narváez JC, Ortega J, Vielma L. Paracoccidioides Brasiliensis, Skin and Lung: A Case Report and Review of the Literature. Abstracts of the VII Latin American Meeting of Pediatric Infectious Diseases. Caracas, Venezuela, 1997.
124. Torres HA, Younes A, Aguilera EA, Luna MA, Tarrand JJ, Hachem RY, Nogueras GM, Raad II, Chemaly R. Cytomegalovirus Pneumonia in Patients with Lymphoma. Abstracts of the 8th Annual Trainee Recognition Day and Research Exposition. The University of Texas M. D. Anderson Cancer Center, Abstract PO17, Houston, Texas, USA, 2004.
125. Raad II, Hanna H, Boktour M, Torres HA, Kontoyiannis DP, Hachem R. The Combination of Caspofungin and Voriconazole as Primary and Salvage Therapy of Invasive Aspergillosis in Hematologic Malignancy Patients. Abstracts of the 2nd Annual Symposium of Infections in Cancer. Houston, Texas, USA, 2008.
126. Torres HA, Mustafayev K, Chiu CY, Ozaras R, Yemisen M, Portillo D, Holguin A, Egge S, Puoti M, Francisco D, Portugal Gonzales J, King GE, Mouliade C, Anolli MP, Lampertico P, Mallet V, Arvelaez Pascucci J, Yepez Guevara E. International Virtual Sessions on Management of Viral Hepatitis in Patients with Cancer. The Global Hepatitis Summit 2025. Los Angeles, California, USA, March 18-21, 2025.
127. Hwang JP, Granwehr B, Torres HA, Suarez-Almazor ME, Giordano TP, Barbo A, Lin HY, Fisch MJ, Chiao EY. HIV testing among patients with cancer before initiation of chemotherapy. The 38th Annual Meeting of the Society of General Internal Medicine (SGIM 2015) April 22-25, 2015,Toronto, Canada.
128. Granwehr B, Merriman K, Grimes R, Shelal Z, Bazerbashi H, Brock P, Gonzalez C, Torres HA, Rice T. Prospective HIV, HBV, HCV Screening in a Cancer Center Emergency Department. International Symposium HIV & Emerging Infectious Diseases (ISHEID), Marseille, France, 2016.
129. Torres HA, Roach LR, Smith K, Mahale P, Raad ll, Adachi JA. Increase rate of patients with Hepatitis C infection treated with antiviral therapy at MD Anderson Cancer Center. Abstracts of the 2011 University of Texas System Clinical Safety and Effectiveness Conference, San Antonio TX.
130. Hwang JP, Suarez-Almazor ME, Palla SL, Huang DS, Torres HA, Fisch MJ, Lok AS. Hepatitis C virus screening prior to chemotherapy. The MASCC/ISOO 2013 International Cancer Care Symposium. Berlin, Germany.
131. Leon R, Martinez E, Guzman A, Torres HA. Reactivation of Hepatitis B. Emerging Trends Conferences.
132. Varma A, Saliba RM, Torres HA, Afrough A, Hosing C, Khouri IF, Nieto Y, Shah ND, Parmar S, Bashir Q, Ahmed S, Jones RB, Kebriaei P, Shpall EJ, Alousi AM, Qazilbash MH, Champlin RE, Popat UR. Outcomes and survival in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. The 79th Annual Meeting of the American College of Gastroenterology Philadelphia, PA. October 17-22.
133. Torres HA, Mahale P. Most patients with hepatitis C virus (HCV)-associated lymphoma present with mild liver disease at cancer diagnosis - A call to revise indications for HCV treatment. The Liver Meeting® 65th Annual Meeting of the American Association for the Study of Liver Diseases, November 7-11, 2014, Boston, MA, and at the American Association for the Study of Liver Diseases (AASLD)/European Association for the Study of the Liver (EASL) 2014 Special Conference on Hepatitis C. New York City, NY. September 12-13.
134. Frigeni M, Visco C, Besson C, Rattotti S, Fontaine H, Goldaniga M, Visentini M, Torres HA, Peveling-Oberhag J, Rossotti R, Zaja F, Rigacci L, Merli M, Dorival C, Alric L, Piazza F, Gentile M, Ferrari A, Pirisi M, Tedeschi A, Defrancesco I, Ferretti W, Bruno R, Hermine O, Arcaini L. Interferon-Free Antiviral Treatment in B-Cell Lymphoproliferative Disorders Associated With Chronic Hepatitis C Virus Infection. The 14th International Conference on Malignant Lymphoma (ICML) Lugano, Switzerland.
135. Pritchard H, Torres HA. Rescue Therapy in Patients with Multiple Failures to Antiviral Therapy against Chronic Hepatitis C infection. 1st Annual Texas Medical Center Antimicrobial Resistance and Stewardship Conference, Houston, TX.
136. Chiu Cy, Zhang HC, Westin J, Hosing C, Torres HA. Hepatitis E Virus Infection in Cancer Patients. International Immunocompromised Host Society (ICHS) 22nd Symposium, Basel, Switzerland.
137. Hwang JP, Heredia N, Asrani S, Foreman J, Warneke CL, Abraham J, Ankoma-Sey C, Ankoma-Sey V, Basen-Engquist K, Booker A, Gambrill C, Green K, Harris C, Le A, Ma J, McNeil L, Nguyen L, Torres HA, Caracostis A. Prevalence of risk factors for liver fibrosis and associations of serum biomarkers with liver fibrosis in a Houston community clinic. The Innovations in Cancer Prevention and Research Conference.
138. Chiu CY, Mustafayev K, Lee HC, Manasanch EE, Yepez Guevara E Samani, Torres HA. Effect of anti-CD38 monoclonal antibodies on hepatitis C virus replication in chronically infected patients with multiple myeloma. 18th Global Hepatitis Summit.

Book Chapters

1. Torres HA, Kontoyiannis DP, Rolston KVI. Infections in Patients with Cancer. In: Holland-Frei Medicine 10th Edition. John Wiley & Sons Inc, 2023.
2. Mak LY, Cruz-Ramón V, Chinchilla-López P, Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Bailey HH, Méndez-Sánchez N, Yuen MF, Hwang JP. Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. In: Am Soc Clin Oncol Educ Book, 262-279, 2018.
3. Davila M, Torres, HA. Management of Reactivation of Hepatitis B and Hepatitis C during antineoplastic therapy. In: Management of Infections in Cancer Patients. 1st. Humana Press, 2011.
4. Torres HA, Kontoyiannis DP. Hyalohyphomycosis (other than Aspergillosis and Penicilliosis). In: Oxford Textbook of Clinical Mycology. Oxford University Press, 252-270, 2011.
5. Torres HA, Boeckh M, Chemaly RF. Viral Infections. In: Internal Medicine Care of Cancer Patient. B C Decker Inc Publisher, 2009.
6. Torres HA, Chemaly RF. Cytomegalovirus Pneumonia. In: Encyclopedia of Molecular Mechanisms of Disease. Springer Publishing House, 2007.

Letters to the Editor

1. Mustafayev, K, Yepez Guevara, E, DiNardo, CD, Jabbour, EJ, Issa, GC, Ratan, R, Pemmaraju, N, Torres, HA. Virologic effect and hepatotoxicity of BCR::ABL1 tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: A prospective study. Leukemia Research 147, 2024.
2. Torres HA, Authors' reply: DM. Current strategies in the management of hepatitis B virus reactivation. Nat Rev Clin Oncol 9: 156-66, 2012.